ARKG
Not rated
No published distribution safety rating is available.
ETF Comparison
ARKG vs HLTH: Which Is the Better Pick in 2026?
A head-to-head comparison of ARK Genomic Revolution ETF and Tema Healthcare AI ETF covering yield, cost, risk, and income potential.
Updated November 6, 2026
No track record yet. HLTH launched within the last six months. The forward distribution rate is left blank until a payout is published.
How these figures are calculated: methodology.
Price and total return
Compare the same available dates. Add a ticker or benchmark below; these controls change the chart only. The snapshot and article describe the original comparison.
Interactive history loads here. The snapshot and period returns remain available when chart history cannot be loaded.
Distribution Safety Score
An estimate of distribution reliability, not price or principal safety, a probability, or a guarantee. Score methodology.
HLTH
Not rated
No published distribution safety rating is available.
Score snapshot as of . Method 1.11.
Side-by-side snapshot
| Metric |  ARKG |  HLTH |
|---|---|---|
| Full name | ARK Genomic Revolution ETF | Tema Healthcare AI ETF |
| Issuer | ARK Invest | Tema ETFs |
| Last Close | $45.45 as of November 6, 2026 | $26.95 as of November 6, 2026 |
| Distribution rate | — | — |
| Distribution Safety Score™ | — | — |
| Expense ratio | 0.75% | 0.75% |
| AUM | $2.15B | $11.7M |
| Distribution frequency | None | None |
| Underlying index | Actively managed (no tracked index recorded) | Actively managed (no tracked index recorded) |
| Objective | Actively managed ETF focused on companies in genomics, gene editing, CRISPR, and molecular diagnostics. | Seeks long-term capital appreciation through an actively managed portfolio of companies applying artificial intelligence across healthcare — including AI-driven drug discovery, diagnostics, medical imaging, medical devices, and healthcare IT platforms. |
| Asset class | Equity | Equity |
| Inception date | 10/31/2014 | 07/21/2026 |
| Beta | 2.21 | — |
| Ex-dividend date | 12/29/2021 | — |
— Distribution rate, Safety-Adjusted Yield, last dividend, and ex-dividend date are not yet available because HLTH launched July 2026; these fields will populate after the first distribution.
Total returns
100% reinvested · ex-date convention. Period returns use this fixed assumption, independent of chart settings. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year.
ARKG has outpaced HLTH over the year to date, posting a 54.02% total return against 5.60%. HLTH has been the steadier holding, though — annualized volatility of 35.9% against 54.9% for ARKG. Figures are total returns: price change plus every distribution reinvested.
| Symbol | YTD cumulative | Since Jul 2026 | Volatility | Sharpe | Sortino | Max drawdown |
|---|---|---|---|---|---|---|
| ARKG | 54.02% | 12.79% | 54.9% | 0.65 | 0.93 | -21.4% |
| HLTH | 5.60% | 5.60% | 35.9% | 0.39 | 0.52 | -12.6% |
Total return with all distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date), split-adjusted, as of November 5, 2026. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year. “Since Jul 2026” measures every fund from July 21, 2026 — the start of shared available history — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the shared window since Jul 2026. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the shared window since Jul 2026) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Not a distribution payer
ARKG (ARK Genomic Revolution ETF) has no distribution rate on file and its distribution frequency is None. ARKG is not a payer. The blank yield is not a zero yield. HLTH (Tema Healthcare AI ETF) has no distribution rate on file and its distribution frequency is None. HLTH is not a payer. The blank yield is not a zero yield.
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Bottom lineWe won't call this one: HLTH launched July 2026, so there is not yet a track record to compare. Compare the strategy, cost and holdings in the sections above and treat any performance figures for the newer ETF as provisional.
Income calculator
See how much monthly income a hypothetical investment would generate in each ETF at current yields.
ETFs14
Total AUM$15.5B
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
ARK Invest is known for actively managed ETFs focused on disruptive innovation and emerging technologies across digital assets and innovation themes. ARK's funds are characterized by concentrated portfolios of high-conviction stock picks and a research-driven approach to identifying companies positioned to benefit from technological transformation.
See our curated list of related YouTube videos on ARKG.
ETFs15
Total AUM$4.23B
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
Tema ETFs is known for offering thematically focused and income-oriented strategies that target specific industries and trends rather than broad market exposure. The issuer's lineup spans both income-generating funds and thematic investments centered on sectors such as defense, healthcare, technology, and infrastructure, with tickers including ARMY, CANC, DSPY, HLTH, LAZR, NASA, and VOLT. Tema's approach appeals to investors seeking targeted exposure to niche market segments, combining specialized industry focus with dividend and yield strategies.
See our curated list of related YouTube videos on HLTH.
Quick verdict
ARKG (ARK Genomic Revolution ETF) and HLTH (Tema Healthcare AI ETF) are both ETFs, but they take different approaches.
ARKG has $2.15B in assets vs $11.7M for HLTH, but HLTH only launched July 2026 — AUM comparisons will become more meaningful as it builds a track record.
Top-holdings overlap
Positions that appear in every fund's top 10. Issuers disclose only the largest weights, so this captures the overlap of the concentrated end of each book — not the full portfolios.
4 shared positions
ARKG 23.6% of its top-10 weight
HLTH 22.9% of its top-10 weight
Deep dive
Yield & income
On a $10,000 investment at current distribution rates, ARKG has no reported distribution yield yet, so a cash estimate is not available, while HLTH has no reported distribution yield yet, so a cash estimate is not available.
ARKG yield—
HLTH yield—
Cost & efficiency
Over 10 years on $10,000, ARKG would cost approximately $750 in fees vs $750 for HLTH (simplified, not compounded). Both charge the same expense ratio.
ARKG ER0.75%
HLTH ER0.75%
Strategy & risk
ARKG is an actively managed ETF, while HLTH is an actively managed ETF built around healthcare exposure.
ARKG beta2.21
HLTH beta—
Fund details
ARKG is managed by ARK Invest (launched 10/31/2014) with $2.15B in assets. HLTH is managed by Tema ETFs (launched 07/21/2026) with $11.7M in assets.
ARKG AUM$2.15B
HLTH AUM$11.7M
Frequently asked questions
Which of ARKG or HLTH pays more dividend income?
Neither ARKG nor HLTH currently reports a distribution yield, so neither is an income fund today. Compare them on holdings, cost, and total return instead.
What is the difference between ARKG and HLTH?
ARKG (ARK Genomic Revolution ETF) is an actively managed ETF, while HLTH (Tema Healthcare AI ETF) is an actively managed ETF built around healthcare exposure. They are issued by ARK Invest and Tema ETFs respectively.
Can I hold both ARKG and HLTH?
You can, but expect meaningful overlap: 4 of the disclosed top-10 positions are shared (see the holdings-overlap section above). Holding both may double up on the same underlying names rather than diversify.
Which has lower fees, ARKG or HLTH?
ARKG and HLTH both charge the same expense ratio of 0.75%, so neither is cheaper on fees — pick based on yield, strategy, or underlying index instead.
How much income does $10,000 in ARKG vs HLTH generate?
At current distribution rates, ARKG does not pay distributions, so there is no cash income to estimate. HLTH does not pay distributions, so there is no cash income to estimate.
Which has performed better historically, ARKG or HLTH?
ARKG has outpaced HLTH over the year to date, posting a 54.02% total return against 5.60%. HLTH has been the steadier holding, though — annualized volatility of 35.9% against 54.9% for ARKG. Figures are total returns: price change plus every distribution reinvested. Past performance does not guarantee future results.
More comparisons to explore
People also compare ARKG with
People also compare HLTH with
Popular comparisons
ARKG vs HLTH — at a glance
Generated November 1, 2026.
Figures quoted in this analysis are from its generation date and may lag the live snapshot table above, which always shows the latest data.
Overview
ARKG and HLTH are both actively managed equity ETFs focused on high-growth segments of healthcare, but they target different innovation vectors. ARKG invests in genomic and genetic technologies—gene editing, CRISPR, molecular diagnostics—while HLTH targets companies deploying artificial intelligence across drug discovery, diagnostics, medical imaging, and healthcare IT. Both charge 0.75%, but they differ sharply in scale, track record, and volatility.
How they differ
The biggest distinction is scope and maturity. ARKG has $2.15B in assets and 12 years of operating history, whereas HLTH launched 07/21/2026 with only $11.7M under management. That size gap matters for liquidity and fund stability; HLTH is a nascent, thinly capitalized vehicle. HLTH's volatility profile relative to equities is not yet available.
Third, the thematic overlap is real but not complete. ARKG's genomics focus is narrower and more established as an investment category; AI-driven healthcare (HLTH's angle) is broader conceptually but newer as a defined strategy. Both may own some of the same companies, but HLTH explicitly targets AI application across the care continuum, while ARKG emphasizes genetic engineering and sequencing technologies.
Who each is best for
ARKG: Fits investors with a long time horizon and high risk tolerance who want concentrated exposure to genomic innovation and can tolerate multiyear drawdowns; the fund's beta suggests it will amplify both upswings and downturns in its underlying holdings.
HLTH: Designed for investors intrigued by AI's healthcare potential but accepting of a brand-new fund with minimal assets and no published performance history; useful as a small exploratory position rather than a core allocation.
Key risks to know
- Concentration and thematic risk: Both funds bet heavily on a narrow subset of healthcare innovation. If genomics or AI-driven drug discovery faces regulatory headwinds, valuation compression, or clinical setbacks, both funds lack diversification into traditional healthcare services or pharma to cushion the blow. Bid-ask spreads may widen during market stress.
- High beta volatility (ARKG): At a beta of 2.21, ARKG's downside swings can be severe during equity sell-offs. Recovery timelines are uncertain, particularly if genomics enthusiasm cools alongside broader growth-stock pullbacks.
- Active management without guardrails: Both funds rely on active stock-picking in rapidly evolving therapeutic categories. There is no guarantee the managers' bets on which companies will dominate genomics or AI in healthcare will prove correct.
Bottom line
If you want an established, liquid fund with years of public data tracking a defined genomic-innovation theme, ARKG offers that foundation despite its volatility. If you're drawn to the AI-healthcare thesis, HLTH provides thematic purity—though its minimal AUM and short existence mean you're holding a largely unproven vehicle. Past performance of ARKG does not predict how either fund will perform going forward.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Learn the method
The metrics behind this comparison, explained in the Academy.
These comparisons follow the Dividend Vision methodology.